Fibromyalgia is one of the most stubborn chronic-pain conditions to manage. Widespread muscle pain, poor sleep, fatigue and “fibro fog” often persist despite medication, and many people are looking for safe, drug-free options they can use alongside their existing treatment.
Red and near-infrared light therapy — known clinically as photobiomodulation (PBM) — has become one of the more researched of those options. A 2026 systematic review pulled together the trials to date, and the picture that emerges is genuinely encouraging, if still early. Here’s what the research actually says — and what it means if you’re considering a panel at home.
What the 2026 review looked at
The review (PubMed ID 42334638) gathered and analysed seven earlier clinical studies of light therapy for fibromyalgia, comparing wavelengths, doses and outcomes across them. Pooling studies this way helps separate a consistent signal from one-off results — though, as the authors themselves stress, the studies varied widely in method, so conclusions should be read as promising rather than definitive.
What the research found
Across the pooled studies, the reviewers reported consistent short-term improvements in the symptoms that matter most day to day:
- Pain. Reductions in pain intensity in the region of 30–55% were reported, measured on the standard 0–10 visual analogue scale. For someone living with fibromyalgia, a shift of that size is the difference between “unbearable” and “manageable.”
- Quality of life. Scores on the widely used SF-36 quality-of-life questionnaire improved substantially in the pooled data — roughly from the high-30s into the mid-50s.
- Tender-point sensitivity. Pressure-pain at fibromyalgia’s characteristic tender points roughly halved.
- Sleep and mood. The review noted additional benefits to sleep quality and psychological well-being — a meaningful bonus, since poor sleep and low mood tend to amplify pain.
- Safety. No serious side effects were reported. This fits the wider evidence: a separate 2026 systematic review of photobiomodulation for chronic pain found that 13 of 14 randomised trials recorded zero adverse events, with the one exception being mild and self-resolving. A 2025 umbrella review also rated the evidence for PBM’s effect on fibromyalgia-related fatigue at moderate certainty — the highest tier it awarded — with a large effect size.
Why light appears to help
Photobiomodulation works at the cellular level. Red and near-infrared light is absorbed by the mitochondria — your cells’ energy factories — where it’s thought to boost energy (ATP) production, reduce oxidative stress, and calm inflammation. In a condition characterised by amplified pain signalling and low cellular energy, those are exactly the levers you’d want to pull. It’s a mechanism, not magic — but it’s a plausible, well-studied one.
The protocol that worked best
One of the most useful things about the 2026 review is that it points toward how to use light therapy, not just whether it works. The protocols that produced the most consistent results shared a pattern:
- Near-infrared wavelengths, roughly in the 808–905 nm range — deep-penetrating light that reaches muscle and tissue, rather than surface-level red only.
- 2–3 sessions per week, over 8–12 weeks — this is a course of treatment, not a one-off.
- Applied across multiple tender points or larger muscular regions, rather than a single small spot.
- Best combined with exercise. Several studies saw the biggest gains when light therapy was paired with aerobic or functional movement — so think of it as part of a routine, not a replacement for one.
What this means for choosing a device
If you’re considering a device with fibromyalgia in mind, the research points to a few practical priorities:
- Coverage matters. Because the protocols treat multiple tender points and larger muscle areas, a full-body panel is far more practical than a small handheld — you can treat the back, hips, shoulders and legs in one session instead of moving a small device around for an hour.
- Wavelengths matter. Look for a device that includes the deeper near-infrared band (around 800–900 nm), not just visible red. Dermfix’s RLF panels emit across a broad 480–1060 nm spectrum, which covers the near-infrared range used in the studies.
- Verified output matters. A light panel only delivers a therapeutic dose if its real irradiance matches its claims. This is why we publish independently measured power-output figures for our panels rather than marketing numbers — the dose is the medicine.
An honest word on the evidence
This research is promising, but it’s early. The reviewers are clear that the studies were small and varied in method, that treatment guidelines aren’t yet standardised, and that larger trials are needed. Red light therapy is best thought of as a safe, drug-free adjunct to work alongside — not replace — the care your doctor provides. It is not a cure for fibromyalgia, and if you have a medical condition you should speak to your healthcare professional before starting any new therapy.
What we can say is that the direction of the evidence is consistent and positive, the safety profile is excellent, and the protocols are simple enough to follow at home.
Explore Dermfix full-body panels
Our RLF series delivers red and near-infrared light across a broad, independently measured spectrum — designed for whole-body sessions, CE-tested, and shipped from EU stock with a 3-year warranty. Browse the range →
References
- Systematic review of light therapy for fibromyalgia, 2026. PubMed ID 42334638 (open-access full text: PMC13290955).
- Photobiomodulation in chronic pain: a systematic review of randomised clinical trials, 2026. PMC12909510.
- Son et al., umbrella review of photobiomodulation health outcomes, 2025 (moderate-certainty evidence for fibromyalgia fatigue).